Roy S. Herbst, MD, PhD
机构: Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven
每年引用次数
引用次数
引用: 105,712
H-指数: 146
I10-指数 : 487
出版物: 998
Gefitinib: current and future status in cancer therapy.
Roy S. Herbst , Merrill S. Kies
Clinical advances in hematology & oncology 1 ( 8) 466 -472
20
2003
Who should go first in trials with scarce agents? The views of potential participants.
Rebecca D. Pentz , Jeremy Sugarman , Anne L. Flamm , Marlene Z. Cohen
IRB: Ethics & Human Research 29 ( 4) 1 -6
2007
Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
Edward Kim , Monique B. Nilsson , Anne S. Tsao , Fei Yang
14
2013
SS-5 Novel therapy for Advanced Non-Small Cell Lung Cancer(NSCLC)
Roy S. Herbst
肺癌 41 ( 5) 398
2001
Angiogenesis and lung cancer: potential for therapy.
Roy S. Herbst , Isaiah J. Fidler
Clinical Cancer Research 6 ( 12) 4604 -4606
40
2000
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.
David J. McConkey , Roy S. Herbst , Hiroki Kuniyasu , Corazon D. Bucana
Cancer Research 60 ( 17) 4959 -4967
184
2000
The anti-vascular and anti-tumor response of human lung cancer growing orthotopically in mice to AEE788, a tyrosine kinase inhibitor of EGFR and VEGFR, is dependent upon EGF/TGFα expression
Roy S. Herbst , Wenjuan Wu , Robert Langley , Cheryl H. Baker
Cancer Research 65 713 -713
2005
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Darren W Davis , Ryan Takamori , Chandrajit P Raut , Henry Q Xiong
Clinical Cancer Research 11 ( 2) 678 -689
39
2005
Thalidomide, Cyclooxygenase-2, and Angiogenesis: Potential for Therapy
Roy S. Herbst , Jennifer E. Tseng , Amir Onn
Clinical Cancer Research 7 ( 11) 3311 -3313
19
2001
Lung-MAP—framework, overview, and design principles
Renata Ferrarotto , Roy S. Herbst , David R. Gandara , Vassiliki A. Papadimitrakopoulou
Chinese clinical oncology 4 ( 3) 36 -36
21
2015
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Roy S. Herbst , Paul A. Bunn
Clinical Cancer Research 9 ( 16) 5813 -5824
128
2003
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Roy S. Herbst , Corazon D. Bucana , Jerald J. Killion , Hisashi Shinohara
Clinical Cancer Research 6 ( 3) 957 -965
143
2000
Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Fadlo R. Khuri , Roy S. Herbst , Hiroki Kuniyasu , Corazon D. Bucana
Clinical Cancer Research 6 ( 3) 790 -797
100
2000
A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer
B. Nebiyou Bekele , Roy S. Herbst , Victoria Allgood , Kenneth J. Holroyd
Clinical Cancer Research 9 ( 11) 4108 -4115
47
2003
Acute in vivo resistance in high-dose therapy.
Roy S. Herbst , Emil Frei , Gulshan Ara , Susan R Keyes
Clinical Cancer Research 4 ( 2) 483 -491
24
1998
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
Danny Rischin , Steven D. Averbuch , Roy S. Herbst , Luca Gianni
Clinical Cancer Research 9 ( 6) 2040 -2048
51
2003
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice
Roy S. Herbst , Wenjuan Wu , Waun Ki Hong , Isaiah J. Fidler
Clinical Cancer Research 9 ( 15) 5532 -5539
192
2003
Targeting protein kinase C beta enhances cell death of non-small cell lung cancer cells.
David G. Menter , Roy S. Herbst , Waun-Ki Hong , Sita Aggarwal
Cancer Epidemiology and Prevention Biomarkers 15
2006
Molecular events surrounding the angiogenic switch of lung cancer
Roy S. Herbst , Jair Bar , Amir Onn
Wolters Kluwer Health Adis (ESP) 113 -134
2
2012
New TNM staging guidelines for non-small-cell lung cancer
Roy S. Herbst , Latha Shivakumar , David R. Gandara , Corey J. Langer
Clinical Lung Cancer 8 ( 9) 529 -531
2007